Merck's pembrolizumab will be tested with leronlimab and sacituzumab in a breast cancer study. It will check safety and tolerability, but no results are reported, so Merck's outlook is unchanged.
This study could provide more information about using Merck's medicine in this cancer. But it will check safety and tolerability, and no findings are reported. There is no demonstrated benefit or harm for Merck.
Follow Merck & Co., Inc. (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRK